Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Calquence head-to-head results versus ibrutinib

June 7, 2021

Lynparza reduced recurrence risk in breast cancer

June 4, 2021

AstraZeneca appoints new Chief Financial Officer

June 4, 2021

Publication of Final Terms

June 2, 2021

Tagrisso approved in EU in early lung cancer

May 28, 2021

Second Price Monitoring Extn

May 27, 2021

Price Monitoring Extension

May 27, 2021

AstraZeneca prices a EUR800m bond offering

May 27, 2021

AstraZeneca prices a $7bn bond offering

May 26, 2021

EMTN programme update - publication of Prospectus

May 25, 2021

Vaxzevria COVID-19 vaccine approved in Japan

May 21, 2021

Shareholders vote in favour of Alexion acquisition

May 11, 2021

Imfinzi + tremelimumab showed survival in POSEIDON

May 7, 2021

Farxiga approved in the US for CKD

May 4, 2021

AZN: First quarter 2021 results

April 30, 2021

Selumetinib recommended for EU approval in NF1

April 26, 2021

Tagrisso adjuvant receives positive CHMP opinion

April 26, 2021

Nirsevimab Phase III trial met primary endpoint

April 26, 2021

US clearance of proposed acquisition of Alexion

April 16, 2021

Tagrisso approved in China in early lung cancer

April 14, 2021

Circular and notice of general meeting

April 12, 2021

Update on Farxiga COVID-19 DARE-19 Phase III trial

April 12, 2021

AZD1222 US Ph3 primary analysis confirms efficacy

March 25, 2021

AstraZeneca US vaccine trial met primary endpoint

March 22, 2021

Divestment of Viela shareholding completed

March 16, 2021

US supply agreement for additional AZD7442 doses

March 16, 2021

Designation of EU home member state

March 4, 2021

US court decision favours Symbicort patents

March 3, 2021

Further update on roxadustat US regulatory review

March 2, 2021

Voluntary withdrawal Imfinzi US bladder indication

February 22, 2021

Lynparza: IDMC recommend early analysis of OlympiA

February 17, 2021

AstraZeneca Non-Executive Board changes

February 11, 2021

AZN: full-year 2020 results

February 11, 2021

Divestment of Crestor in Europe completed

February 10, 2021

Update on KESTREL Phase III trial for Imfinzi

February 5, 2021

Forxiga approved in China for heart failure

February 4, 2021

AstraZeneca agrees to divest Viela shareholding

February 1, 2021

COVID-19 vaccine authorised for use by the EU

February 1, 2021

COVID-19 vaccine receives positive opinion in EU

January 29, 2021

Block listing application

January 26, 2021

Symbicort approved in China for mild asthma

January 26, 2021

Calquence approved in Japan for CLL

January 25, 2021

Calquence met primary endpoint against ibrutinib

January 25, 2021

Enhertu approved in the EU for breast cancer

January 20, 2021

Enhertu approved in the US for gastric cancer

January 18, 2021

Imfinzi new dosing approved in EU

January 15, 2021

Farxiga granted US Priority Review for CKD

January 6, 2021

Atacand divestment in over 70 countries completed

January 4, 2021

AstraZeneca's COVID-19 vaccine authorised in UK

December 30, 2020

Lynparza approved in Japan for three cancers

December 29, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 249 decks. Every deck is listed under its year.